Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry. (Q38736346)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

title

Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Filip S Ekholm

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Henna Pynnönen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Anja Vilkman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Virve Pitkänen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Jari Helin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Juhani Saarinen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

publication date

27 October 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

2501-2505

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

26 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Antibody-drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Antibody-drug conjugates in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Antibody-drug conjugates: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Antibody-targeted drugs for the therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Maturing antibody-drug conjugate pipeline hits 30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Trastuzumab emtansine: mechanisms of action and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Reductive amination of carbohydrates using NaBH(OAc)3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

The direct coupling of oligosaccharides to proteins and derivatized gels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

21 January 2018

Carbohydrate microarrays

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Carbohydrate arrays as tools for research and diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Carbohydrate microarrays as powerful tools in studies of carbohydrate-mediated biological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Preparation of poly(ethylene glycol) protected nanoparticles with variable bioconjugate ligand density

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Bioconjugation via azide-Staudinger ligation: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Chemically-selective surface glyco-functionalization of liposomes through Staudinger ligation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Carbohydrate and protein immobilization onto solid surfaces by sequential Diels-Alder and azide-alkyne cycloadditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

From mechanism to mouse: a tale of two bioorthogonal reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Rapid oxime and hydrazone ligations with aromatic aldehydes for biomolecular labeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

High-efficiency labeling of sialylated glycoproteins on living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Thiol-ene click chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Bioorthogonal chemistry: strategies and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Azide: a unique dipole for metal-free bioorthogonal ligations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Proline cis-trans isomerization controls autoinhibition of a signaling protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Kinetics and equilibria of cis/trans isomerization of backbone amide bonds in peptoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

New developments for antibody-drug conjugate-based therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Enhancing the Proline Effect: Pseudo-Prolines for TailoringCis/TransIsomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Suppression of tumour growth in mice by a drug–antibody conjugate using a novel approach to linkage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

Antibody as carrier of chlorambucil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

7 January 2021

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

7 January 2021

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

7 January 2021

Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

7 January 2021

Fluorophore-assisted carbohydrate electrophoresis (FACE) of oligosaccharides: efficiency of labelling and high-resolution separation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

7 January 2021

On the preparation of carbohydrate-protein conjugates using the traceless Staudinger ligation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.201600372

1 reference

7 January 2021

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201600372

7 January 2021

Identifiers

DOI

10.1002/CMDC.201600372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27786414%20AND%20SRC:MED&resulttype=core&format=json